SCHEMBL30469876

SCHEMBL30469876

COc1cc(C(=O)Cl)ccc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA4 P22748 1/20 0.48
CA6 P23280 1/20 0.48
CA7 P43166 1/20 0.48
TPMT P51580 1/20 0.48
CA9 Q16790 1/20 0.48
CA14 Q9ULX7 1/20 0.48
TAS1R3 Q7RTX0 1/20 0.48
TAS1R1 Q7RTX1 1/20 0.48
SLC22A6 Q4U2R8 1/20 0.47
SLC22A8 Q8TCC7 1/20 0.47
MEN1 O00255 1/20 0.47
RAB9A P51151 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22035 1.00 TSHR (0.50) TSHRCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL1164664 0.85 ALOX15 (0.51) TSHRCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL29521706 0.84 TSHR (0.70) TSHRCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL184025 0.84 TSHR (0.70) TSHRCYP1A2CYP3A4CYP2C9CYP2C19
Hydrochloric Acid SCHEMBL8590467 0.82 TSHR (0.68) TSHRCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL10885938 0.82 TSHR (0.52) TSHRCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL503429 0.82 CA12 (0.71) TSHRCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL801748 0.82 LMNA (0.57) TSHRCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL31406172 0.82 CA12 (0.71) TSHRCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL21943579 0.81 ACHE (0.56) TSHRRAB9AHTTPKMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4188920-A1 PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS Tango Therapeutics, Inc. (US) 2023-06-07 EP disclosed